[
    {
        "id": 2919,
        "drug_name": "ZEPOSIA (ozanimod)",
        "clinical_trial_id": "NCT02531126",
        "has_trial_insight_page": 0,
        "indication": "Ulcerative Colitis",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-05-27",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20210527005878\/en\/",
        "note": "FDA approval announced May 27, 2021.",
        "company_entity_id": 376,
        "company_ticker": "BMY",
        "company_name": "Bristol-Myers Squibb Company",
        "company_price": "54.4000",
        "company_change": 0.04,
        "company_percent_change": 0.07,
        "company_optionable": 1,
        "company_number_of_shares": 2022193411,
        "price_change_sparkline": [
            [
                48.87,
                1706677200
            ],
            [
                48.67,
                1706763600
            ],
            [
                48.71,
                1706850000
            ],
            [
                47.98,
                1707109200
            ],
            [
                49.26,
                1707195600
            ],
            [
                48.64,
                1707282000
            ],
            [
                48.71,
                1707368400
            ],
            [
                49.81,
                1707454800
            ],
            [
                49.75,
                1707714000
            ],
            [
                48.71,
                1707800400
            ],
            [
                48.89,
                1707886800
            ],
            [
                49.44,
                1707973200
            ],
            [
                49.86,
                1708059600
            ],
            [
                49.86,
                1708405200
            ],
            [
                50.91,
                1708491600
            ],
            [
                51.33,
                1708578000
            ],
            [
                51.66,
                1708664400
            ],
            [
                50.52,
                1708923600
            ],
            [
                50.51,
                1709010000
            ],
            [
                50.92,
                1709096400
            ],
            [
                50.75,
                1709182800
            ],
            [
                50.89,
                1709269200
            ],
            [
                50.92,
                1709528400
            ],
            [
                51.82,
                1709614800
            ],
            [
                53.38,
                1709701200
            ],
            [
                53.28,
                1709787600
            ],
            [
                53.79,
                1709874000
            ],
            [
                54.36,
                1710129600
            ],
            [
                54.4,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2550,
        "drug_name": "NURTEC ODT (Rimegepant)",
        "clinical_trial_id": "NCT03732638",
        "has_trial_insight_page": 0,
        "indication": "Migraine - preventative",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-05-27",
        "link": "https:\/\/www.prnewswire.com\/news-releases\/fda-approves-biohavens-nurtec-odt-rimegepant-for-prevention-now-the-first-and-only-migraine-medication-for-both-acute-and-preventive-treatment-301301304.html",
        "note": "FDA approval announced May 27, 2021.",
        "company_entity_id": 387,
        "company_ticker": "PFE",
        "company_name": "Pfizer Inc.",
        "company_price": "28.0100",
        "company_change": -0.36,
        "company_percent_change": -1.27,
        "company_optionable": 1,
        "company_number_of_shares": 5646778425,
        "price_change_sparkline": [
            [
                27.08,
                1706677200
            ],
            [
                27.29,
                1706763600
            ],
            [
                26.93,
                1706850000
            ],
            [
                26.57,
                1707109200
            ],
            [
                27.5,
                1707195600
            ],
            [
                27.56,
                1707282000
            ],
            [
                27.57,
                1707368400
            ],
            [
                27.56,
                1707454800
            ],
            [
                27.66,
                1707714000
            ],
            [
                26.97,
                1707800400
            ],
            [
                27.11,
                1707886800
            ],
            [
                27.51,
                1707973200
            ],
            [
                27.62,
                1708059600
            ],
            [
                27.59,
                1708405200
            ],
            [
                27.67,
                1708491600
            ],
            [
                27.55,
                1708578000
            ],
            [
                27.76,
                1708664400
            ],
            [
                27.18,
                1708923600
            ],
            [
                26.89,
                1709010000
            ],
            [
                27.04,
                1709096400
            ],
            [
                26.56,
                1709182800
            ],
            [
                26.59,
                1709269200
            ],
            [
                25.89,
                1709528400
            ],
            [
                26.08,
                1709614800
            ],
            [
                27.19,
                1709701200
            ],
            [
                26.79,
                1709787600
            ],
            [
                27.22,
                1709874000
            ],
            [
                28.37,
                1710129600
            ],
            [
                28.01,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2550,
        "drug_name": "NURTEC ODT (Rimegepant)",
        "clinical_trial_id": "NCT03732638",
        "has_trial_insight_page": 0,
        "indication": "Migraine - preventative",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-05-27",
        "link": "https:\/\/www.prnewswire.com\/news-releases\/fda-approves-biohavens-nurtec-odt-rimegepant-for-prevention-now-the-first-and-only-migraine-medication-for-both-acute-and-preventive-treatment-301301304.html",
        "note": "FDA approval announced May 27, 2021.",
        "company_entity_id": 409,
        "company_ticker": "BHVN",
        "company_name": "Biohaven Ltd.",
        "company_price": "58.5800",
        "company_change": 3.2,
        "company_percent_change": 5.78,
        "company_optionable": 1,
        "company_number_of_shares": 81579914,
        "price_change_sparkline": [
            [
                44.48,
                1706677200
            ],
            [
                45,
                1706763600
            ],
            [
                44.79,
                1706850000
            ],
            [
                47.16,
                1707109200
            ],
            [
                47.21,
                1707195600
            ],
            [
                47.26,
                1707282000
            ],
            [
                46.92,
                1707368400
            ],
            [
                48.55,
                1707454800
            ],
            [
                48.71,
                1707714000
            ],
            [
                46.95,
                1707800400
            ],
            [
                47.12,
                1707886800
            ],
            [
                49.11,
                1707973200
            ],
            [
                49.5,
                1708059600
            ],
            [
                47.24,
                1708405200
            ],
            [
                46.57,
                1708491600
            ],
            [
                47.33,
                1708578000
            ],
            [
                47.31,
                1708664400
            ],
            [
                46.18,
                1708923600
            ],
            [
                47.66,
                1709010000
            ],
            [
                47.3,
                1709096400
            ],
            [
                48.14,
                1709182800
            ],
            [
                49.54,
                1709269200
            ],
            [
                56.39,
                1709528400
            ],
            [
                58.65,
                1709614800
            ],
            [
                58.13,
                1709701200
            ],
            [
                58.05,
                1709787600
            ],
            [
                57.97,
                1709874000
            ],
            [
                55.38,
                1710129600
            ],
            [
                58.58,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 6367,
        "drug_name": "LUMAKRAS (Sotorasib)",
        "clinical_trial_id": "NCT03600883",
        "has_trial_insight_page": 0,
        "indication": "Non-small cell lung cancer (NSCLC)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-05-28",
        "link": "https:\/\/www.prnewswire.com\/news-releases\/fda-approves-lumakras-sotorasib-the-first-and-only-targeted-treatment-for-patients-with-kras-g12c-mutated-locally-advanced-or-metastatic-non-small-cell-lung-cancer-301301808.html",
        "note": "FDA approval announced May 28, 2021.",
        "company_entity_id": 372,
        "company_ticker": "AMGN",
        "company_name": "Amgen Inc.",
        "company_price": "276.5400",
        "company_change": 1.18,
        "company_percent_change": 0.43,
        "company_optionable": 1,
        "company_number_of_shares": 535918901,
        "price_change_sparkline": [
            [
                311.832823699025,
                1706677200
            ],
            [
                322.053272003295,
                1706763600
            ],
            [
                320.693853151174,
                1706850000
            ],
            [
                319.483275779212,
                1707109200
            ],
            [
                313.62884422628,
                1707195600
            ],
            [
                293.584858231498,
                1707282000
            ],
            [
                292.572736166415,
                1707368400
            ],
            [
                288.871544693121,
                1707454800
            ],
            [
                292.155980021969,
                1707714000
            ],
            [
                288.236487711108,
                1707800400
            ],
            [
                287.829654332006,
                1707886800
            ],
            [
                289.07,
                1707973200
            ],
            [
                283.7,
                1708059600
            ],
            [
                283.51,
                1708405200
            ],
            [
                283.46,
                1708491600
            ],
            [
                285.18,
                1708578000
            ],
            [
                289.18,
                1708664400
            ],
            [
                286.37,
                1708923600
            ],
            [
                278.49,
                1709010000
            ],
            [
                277.46,
                1709096400
            ],
            [
                273.83,
                1709182800
            ],
            [
                280.33,
                1709269200
            ],
            [
                279.39,
                1709528400
            ],
            [
                276.65,
                1709614800
            ],
            [
                276.59,
                1709701200
            ],
            [
                272.86,
                1709787600
            ],
            [
                273.75,
                1709874000
            ],
            [
                275.36,
                1710129600
            ],
            [
                276.54,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5901,
        "drug_name": "TRUSELTIQ (Infigratinib)",
        "clinical_trial_id": "NCT02150967",
        "has_trial_insight_page": 0,
        "indication": "Cholangiocarcinoma",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-06-01",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20210601005321\/en\/",
        "note": "FDA approval announced June 1, 2021.",
        "company_entity_id": 680,
        "company_ticker": "BBIO",
        "company_name": "BridgeBio Pharma Inc.",
        "company_price": "28.7000",
        "company_change": -0.24,
        "company_percent_change": -0.83,
        "company_optionable": 1,
        "company_number_of_shares": 175831536,
        "price_change_sparkline": [
            [
                34.29,
                1706677200
            ],
            [
                33.31,
                1706763600
            ],
            [
                33.91,
                1706850000
            ],
            [
                33.63,
                1707109200
            ],
            [
                34.02,
                1707195600
            ],
            [
                33.77,
                1707282000
            ],
            [
                32.96,
                1707368400
            ],
            [
                34.47,
                1707454800
            ],
            [
                35.65,
                1707714000
            ],
            [
                33.57,
                1707800400
            ],
            [
                34.37,
                1707886800
            ],
            [
                39.23,
                1707973200
            ],
            [
                37.21,
                1708059600
            ],
            [
                35.95,
                1708405200
            ],
            [
                34.16,
                1708491600
            ],
            [
                33.6,
                1708578000
            ],
            [
                34,
                1708664400
            ],
            [
                34.87,
                1708923600
            ],
            [
                35.73,
                1709010000
            ],
            [
                35.29,
                1709096400
            ],
            [
                34.15,
                1709182800
            ],
            [
                35.63,
                1709269200
            ],
            [
                32.355,
                1709528400
            ],
            [
                29.6,
                1709614800
            ],
            [
                29.45,
                1709701200
            ],
            [
                30,
                1709787600
            ],
            [
                28.98,
                1709874000
            ],
            [
                28.94,
                1710129600
            ],
            [
                28.7,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5901,
        "drug_name": "TRUSELTIQ (Infigratinib)",
        "clinical_trial_id": "NCT02150967",
        "has_trial_insight_page": 0,
        "indication": "Cholangiocarcinoma",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-06-01",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20210601005321\/en\/",
        "note": "FDA approval announced June 1, 2021.",
        "company_entity_id": 1022,
        "company_ticker": "LIAN",
        "company_name": "LianBio",
        "company_price": "4.9500",
        "company_change": 0.03,
        "company_percent_change": 0.61,
        "company_optionable": 0,
        "company_number_of_shares": 108062638,
        "price_change_sparkline": [
            [
                4.11,
                1706677200
            ],
            [
                4.18,
                1706763600
            ],
            [
                4.13,
                1706850000
            ],
            [
                4.12,
                1707109200
            ],
            [
                4.17,
                1707195600
            ],
            [
                4.1,
                1707282000
            ],
            [
                4.09,
                1707368400
            ],
            [
                4.14,
                1707454800
            ],
            [
                4.04,
                1707714000
            ],
            [
                4.8,
                1707800400
            ],
            [
                4.76,
                1707886800
            ],
            [
                4.78,
                1707973200
            ],
            [
                4.77,
                1708059600
            ],
            [
                4.79,
                1708405200
            ],
            [
                4.79,
                1708491600
            ],
            [
                4.79,
                1708578000
            ],
            [
                4.79,
                1708664400
            ],
            [
                4.81,
                1708923600
            ],
            [
                4.815,
                1709010000
            ],
            [
                4.82,
                1709096400
            ],
            [
                4.84,
                1709182800
            ],
            [
                4.88,
                1709269200
            ],
            [
                4.89,
                1709528400
            ],
            [
                4.92,
                1709614800
            ],
            [
                4.94,
                1709701200
            ],
            [
                4.9,
                1709787600
            ],
            [
                4.93,
                1709874000
            ],
            [
                4.92,
                1710129600
            ],
            [
                4.95,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2615,
        "drug_name": "LYBALVI (olanzapine\/samidorphan)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Schizophrenia, bipolar",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-06-01",
        "link": "https:\/\/www.prnewswire.com\/news-releases\/alkermes-announces-fda-approval-of-lybalvi-for-the-treatment-of-schizophrenia-and-bipolar-i-disorder-301302527.html",
        "note": "FDA approval announced June 1, 2021.",
        "company_entity_id": 31,
        "company_ticker": "ALKS",
        "company_name": "Alkermes plc",
        "company_price": "28.4700",
        "company_change": -0.13,
        "company_percent_change": -0.44999999999999996,
        "company_optionable": 1,
        "company_number_of_shares": 167076133,
        "price_change_sparkline": [
            [
                27.05,
                1706677200
            ],
            [
                26.94,
                1706763600
            ],
            [
                26.74,
                1706850000
            ],
            [
                26.4,
                1707109200
            ],
            [
                27.04,
                1707195600
            ],
            [
                26.7,
                1707282000
            ],
            [
                26.77,
                1707368400
            ],
            [
                27.32,
                1707454800
            ],
            [
                28.52,
                1707714000
            ],
            [
                27.23,
                1707800400
            ],
            [
                27.99,
                1707886800
            ],
            [
                32.56,
                1707973200
            ],
            [
                32.18,
                1708059600
            ],
            [
                30.39,
                1708405200
            ],
            [
                29.18,
                1708491600
            ],
            [
                28.91,
                1708578000
            ],
            [
                29.57,
                1708664400
            ],
            [
                30.04,
                1708923600
            ],
            [
                29.7,
                1709010000
            ],
            [
                29.8,
                1709096400
            ],
            [
                29.69,
                1709182800
            ],
            [
                30.24,
                1709269200
            ],
            [
                29.92,
                1709528400
            ],
            [
                29.76,
                1709614800
            ],
            [
                28.94,
                1709701200
            ],
            [
                29.45,
                1709787600
            ],
            [
                29.25,
                1709874000
            ],
            [
                28.6,
                1710129600
            ],
            [
                28.47,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 6081,
        "drug_name": "BREXAFEMME (ibrexafungerp)",
        "clinical_trial_id": "NCT03987620",
        "has_trial_insight_page": 0,
        "indication": "Vulvovaginal candidiasis (VVC)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-06-02",
        "link": "https:\/\/ir.scynexis.com\/press-releases\/detail\/240\/scynexis-announces-fda-approval-of-brexafemme",
        "note": "FDA approval announced June 2, 2021.",
        "company_entity_id": 275,
        "company_ticker": "SCYX",
        "company_name": "SCYNEXIS Inc.",
        "company_price": "1.6000",
        "company_change": -0.010000000000000009,
        "company_percent_change": -0.62,
        "company_optionable": 1,
        "company_number_of_shares": 37207799,
        "price_change_sparkline": [
            [
                2.06,
                1706677200
            ],
            [
                2.11,
                1706763600
            ],
            [
                2.14,
                1706850000
            ],
            [
                2.05,
                1707109200
            ],
            [
                1.995,
                1707195600
            ],
            [
                2,
                1707282000
            ],
            [
                1.92,
                1707368400
            ],
            [
                1.925,
                1707454800
            ],
            [
                1.81,
                1707714000
            ],
            [
                1.8,
                1707800400
            ],
            [
                1.82,
                1707886800
            ],
            [
                1.78,
                1707973200
            ],
            [
                1.72,
                1708059600
            ],
            [
                1.77,
                1708405200
            ],
            [
                1.7,
                1708491600
            ],
            [
                1.65,
                1708578000
            ],
            [
                1.68,
                1708664400
            ],
            [
                1.72,
                1708923600
            ],
            [
                1.7,
                1709010000
            ],
            [
                1.7,
                1709096400
            ],
            [
                1.62,
                1709182800
            ],
            [
                1.62,
                1709269200
            ],
            [
                1.63,
                1709528400
            ],
            [
                1.65,
                1709614800
            ],
            [
                1.67,
                1709701200
            ],
            [
                1.69,
                1709787600
            ],
            [
                1.66,
                1709874000
            ],
            [
                1.61,
                1710129600
            ],
            [
                1.6,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 1957,
        "drug_name": "TEMBEXA (brincidofovir)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Smallpox",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-06-04",
        "link": "https:\/\/www.globenewswire.com\/news-release\/2021\/06\/04\/2242292\/25619\/en\/Chimerix-Receives-U-S-Food-and-Drug-Administration-Approval-for-TEMBEXA-brincidofovir-for-the-Treatment-of-Smallpox.html",
        "note": "FDA approval announced June 4, 2021.",
        "company_entity_id": 94,
        "company_ticker": "CMRX",
        "company_name": "Chimerix Inc.",
        "company_price": "1.1800",
        "company_change": -0.06000000000000005,
        "company_percent_change": -4.84,
        "company_optionable": 1,
        "company_number_of_shares": 89210356,
        "price_change_sparkline": [
            [
                0.9364,
                1706677200
            ],
            [
                0.9308,
                1706763600
            ],
            [
                0.9315,
                1706850000
            ],
            [
                0.9055,
                1707109200
            ],
            [
                0.929,
                1707195600
            ],
            [
                0.9179,
                1707282000
            ],
            [
                0.9101,
                1707368400
            ],
            [
                0.93,
                1707454800
            ],
            [
                1.05,
                1707714000
            ],
            [
                1.03,
                1707800400
            ],
            [
                1.05,
                1707886800
            ],
            [
                1.04,
                1707973200
            ],
            [
                1.15,
                1708059600
            ],
            [
                1.22,
                1708405200
            ],
            [
                1.19,
                1708491600
            ],
            [
                1.18,
                1708578000
            ],
            [
                1.18,
                1708664400
            ],
            [
                1.19,
                1708923600
            ],
            [
                1.205,
                1709010000
            ],
            [
                1.24,
                1709096400
            ],
            [
                1.15,
                1709182800
            ],
            [
                1.17,
                1709269200
            ],
            [
                1.18,
                1709528400
            ],
            [
                1.21,
                1709614800
            ],
            [
                1.25,
                1709701200
            ],
            [
                1.26,
                1709787600
            ],
            [
                1.26,
                1709874000
            ],
            [
                1.24,
                1710129600
            ],
            [
                1.18,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 7128,
        "drug_name": "RYPLAZIM (plasminogen)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Congenital plasminogen deficiency (C-PLGD)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-06-04",
        "link": "https:\/\/www.prnewswire.com\/news-releases\/liminal-biosciences-announces-fda-approval-for-its-biologics-license-application-for-ryplazim-plasminogen-human-tvmh-301306233.html",
        "note": "FDA approval announced June 4, 2021.",
        "company_entity_id": 840,
        "company_ticker": "LMNL",
        "company_name": "Liminal BioSciences Inc.",
        "company_price": "8.5000",
        "company_change": 0,
        "company_percent_change": 0,
        "company_optionable": 0,
        "company_number_of_shares": 3249534,
        "statuses": []
    },
    {
        "id": 7758,
        "drug_name": "ULTOMIRIS (ravulizumab-cwvz)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Paroxysmal Nocturnal Hemoglobinuria (PNH) - children",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-06-07",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20210607005638\/en\/",
        "note": "FDA approval announced June 7, 2021.",
        "company_entity_id": 374,
        "company_ticker": "AZN",
        "company_name": "AstraZeneca PLC",
        "company_price": "67.4000",
        "company_change": -0.27,
        "company_percent_change": -0.4,
        "company_optionable": 1,
        "company_number_of_shares": 3100378676,
        "price_change_sparkline": [
            [
                65.6319311986485,
                1706677200
            ],
            [
                65.8387545112493,
                1706763600
            ],
            [
                64.647058281502,
                1706850000
            ],
            [
                64.1546218229287,
                1707109200
            ],
            [
                66.0258803655072,
                1707195600
            ],
            [
                65.5432926361053,
                1707282000
            ],
            [
                62.5591276971512,
                1707368400
            ],
            [
                61.3181878215465,
                1707454800
            ],
            [
                60.4810458419719,
                1707714000
            ],
            [
                60.1067941334562,
                1707800400
            ],
            [
                60.7272640712585,
                1707886800
            ],
            [
                61.8894141134915,
                1707973200
            ],
            [
                63.2977823850111,
                1708059600
            ],
            [
                64.056134531214,
                1708405200
            ],
            [
                64.1053781770713,
                1708491600
            ],
            [
                64.13,
                1708578000
            ],
            [
                65.83,
                1708664400
            ],
            [
                65.93,
                1708923600
            ],
            [
                66.33,
                1709010000
            ],
            [
                65.35,
                1709096400
            ],
            [
                64.16,
                1709182800
            ],
            [
                64.6,
                1709269200
            ],
            [
                64.79,
                1709528400
            ],
            [
                64.81,
                1709614800
            ],
            [
                65.27,
                1709701200
            ],
            [
                66.19,
                1709787600
            ],
            [
                66.5,
                1709874000
            ],
            [
                67.67,
                1710129600
            ],
            [
                67.4,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2613,
        "drug_name": "ADUHELM (Aducanumab)",
        "clinical_trial_id": "NCT02484547",
        "has_trial_insight_page": 0,
        "indication": "Alzheimer\u2019s disease",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-06-07",
        "link": "https:\/\/www.biogencdn.com\/us\/aduhelm-pi.pdf",
        "note": "FDA approval announced June 7, 2021.",
        "company_entity_id": 375,
        "company_ticker": "BIIB",
        "company_name": "Biogen Inc.",
        "company_price": "227.3600",
        "company_change": -2.71,
        "company_percent_change": -1.1800000000000002,
        "company_optionable": 1,
        "company_number_of_shares": 145360798,
        "price_change_sparkline": [
            [
                246.66,
                1706677200
            ],
            [
                247.83,
                1706763600
            ],
            [
                243.72,
                1706850000
            ],
            [
                241.84,
                1707109200
            ],
            [
                245.55,
                1707195600
            ],
            [
                240.54,
                1707282000
            ],
            [
                240.3,
                1707368400
            ],
            [
                240.98,
                1707454800
            ],
            [
                244.74,
                1707714000
            ],
            [
                226.65,
                1707800400
            ],
            [
                220.74,
                1707886800
            ],
            [
                223.35,
                1707973200
            ],
            [
                219.08,
                1708059600
            ],
            [
                219.21,
                1708405200
            ],
            [
                221.11,
                1708491600
            ],
            [
                222.48,
                1708578000
            ],
            [
                223.32,
                1708664400
            ],
            [
                223.71,
                1708923600
            ],
            [
                223.94,
                1709010000
            ],
            [
                221.74,
                1709096400
            ],
            [
                216.99,
                1709182800
            ],
            [
                220.95,
                1709269200
            ],
            [
                221.02,
                1709528400
            ],
            [
                217.23,
                1709614800
            ],
            [
                217.56,
                1709701200
            ],
            [
                219.36,
                1709787600
            ],
            [
                223.24,
                1709874000
            ],
            [
                230.07,
                1710129600
            ],
            [
                227.36,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 7070,
        "drug_name": "PREVNAR 20",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Pneumococcal conjugate vaccine (18 yrs +)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-06-08",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20210608006149\/en\/",
        "note": "https:\/\/www.businesswire.com\/news\/home\/20210608006149\/en\/",
        "company_entity_id": 387,
        "company_ticker": "PFE",
        "company_name": "Pfizer Inc.",
        "company_price": "28.0100",
        "company_change": -0.36,
        "company_percent_change": -1.27,
        "company_optionable": 1,
        "company_number_of_shares": 5646778425,
        "price_change_sparkline": [
            [
                27.08,
                1706677200
            ],
            [
                27.29,
                1706763600
            ],
            [
                26.93,
                1706850000
            ],
            [
                26.57,
                1707109200
            ],
            [
                27.5,
                1707195600
            ],
            [
                27.56,
                1707282000
            ],
            [
                27.57,
                1707368400
            ],
            [
                27.56,
                1707454800
            ],
            [
                27.66,
                1707714000
            ],
            [
                26.97,
                1707800400
            ],
            [
                27.11,
                1707886800
            ],
            [
                27.51,
                1707973200
            ],
            [
                27.62,
                1708059600
            ],
            [
                27.59,
                1708405200
            ],
            [
                27.67,
                1708491600
            ],
            [
                27.55,
                1708578000
            ],
            [
                27.76,
                1708664400
            ],
            [
                27.18,
                1708923600
            ],
            [
                26.89,
                1709010000
            ],
            [
                27.04,
                1709096400
            ],
            [
                26.56,
                1709182800
            ],
            [
                26.59,
                1709269200
            ],
            [
                25.89,
                1709528400
            ],
            [
                26.08,
                1709614800
            ],
            [
                27.19,
                1709701200
            ],
            [
                26.79,
                1709787600
            ],
            [
                27.22,
                1709874000
            ],
            [
                28.37,
                1710129600
            ],
            [
                28.01,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 6999,
        "drug_name": "TRIKAFTA (elexacaftor\/tezacaftor\/ivacaftor and ivacaftor)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Children (6-11 years old) who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a mutation in the CFTR gene that is responsive",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-06-09",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20210609005466\/en\/",
        "note": "FDA approval announced June 9, 2021.",
        "company_entity_id": 306,
        "company_ticker": "VRTX",
        "company_name": "Vertex Pharmaceuticals Incorporated",
        "company_price": "412.4500",
        "company_change": -2.02,
        "company_percent_change": -0.49,
        "company_optionable": 1,
        "company_number_of_shares": 258307816,
        "price_change_sparkline": [
            [
                433.38,
                1706677200
            ],
            [
                433.87,
                1706763600
            ],
            [
                424.68,
                1706850000
            ],
            [
                428.89,
                1707109200
            ],
            [
                416.13,
                1707195600
            ],
            [
                419.08,
                1707282000
            ],
            [
                423.06,
                1707368400
            ],
            [
                422.91,
                1707454800
            ],
            [
                418.53,
                1707714000
            ],
            [
                416.04,
                1707800400
            ],
            [
                417.88,
                1707886800
            ],
            [
                426.29,
                1707973200
            ],
            [
                422.2,
                1708059600
            ],
            [
                420.64,
                1708405200
            ],
            [
                419.63,
                1708491600
            ],
            [
                426.78,
                1708578000
            ],
            [
                430.11,
                1708664400
            ],
            [
                433.48,
                1708923600
            ],
            [
                430.92,
                1709010000
            ],
            [
                426.97,
                1709096400
            ],
            [
                420.74,
                1709182800
            ],
            [
                432.76,
                1709269200
            ],
            [
                424.03,
                1709528400
            ],
            [
                415.44,
                1709614800
            ],
            [
                411.85,
                1709701200
            ],
            [
                410.54,
                1709787600
            ],
            [
                413.59,
                1709874000
            ],
            [
                414.47,
                1710129600
            ],
            [
                412.45,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5758,
        "drug_name": "REZIPRES (ephedrine hydrochloride injection)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Injectable hospital product",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-06-15",
        "link": "https:\/\/www.globenewswire.com\/news-release\/2021\/06\/15\/2247536\/0\/en\/Eton-Pharmaceuticals-Announces-FDA-Approval-of-Rezipres-Ephedrine-Hydrochloride-Injection.html",
        "note": "FDA approval announced June 15, 2021.",
        "company_entity_id": 611,
        "company_ticker": "ETON",
        "company_name": "Eton Pharmaceuticals Inc.",
        "company_price": "4.4000",
        "company_change": -0.16000000000000003,
        "company_percent_change": -3.51,
        "company_optionable": 1,
        "company_number_of_shares": 25658396,
        "price_change_sparkline": [
            [
                4.67,
                1706677200
            ],
            [
                4.6,
                1706763600
            ],
            [
                4.49,
                1706850000
            ],
            [
                4.58,
                1707109200
            ],
            [
                4.72,
                1707195600
            ],
            [
                4.58,
                1707282000
            ],
            [
                4.41,
                1707368400
            ],
            [
                4.41,
                1707454800
            ],
            [
                4.41,
                1707714000
            ],
            [
                4.42,
                1707800400
            ],
            [
                4.39,
                1707886800
            ],
            [
                4.59,
                1707973200
            ],
            [
                4.4,
                1708059600
            ],
            [
                4.36,
                1708405200
            ],
            [
                4.45,
                1708491600
            ],
            [
                4.47,
                1708578000
            ],
            [
                4.47,
                1708664400
            ],
            [
                4.47,
                1708923600
            ],
            [
                4.49,
                1709010000
            ],
            [
                4.48,
                1709096400
            ],
            [
                4.45,
                1709182800
            ],
            [
                4.46,
                1709269200
            ],
            [
                4.47,
                1709528400
            ],
            [
                4.38,
                1709614800
            ],
            [
                4.33,
                1709701200
            ],
            [
                4.49,
                1709787600
            ],
            [
                4.5,
                1709874000
            ],
            [
                4.56,
                1710129600
            ],
            [
                4.4,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 4443,
        "drug_name": "StrataGraft",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Deep partial thickness severe burns - skin defects",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-06-15",
        "link": "https:\/\/www.prnewswire.com\/news-releases\/mallinckrodt-announces-us-fda-approval-of-stratagraft-allogeneic-cultured-keratinocytes-and-dermal-fibroblasts-in-murine-collagen---dsat-301313193.html",
        "note": "FDA approval June 15, 2021.",
        "company_entity_id": 887,
        "company_ticker": "MNKKQ",
        "company_name": "Mallinckrodt plc",
        "company_price": "0.0200",
        "company_change": 0,
        "company_percent_change": 0,
        "company_optionable": 0,
        "company_number_of_shares": 13371707,
        "statuses": []
    },
    {
        "id": 4708,
        "drug_name": "AYVAKIT (avapritinib)",
        "clinical_trial_id": "NCT03580655",
        "has_trial_insight_page": 0,
        "indication": "Advanced Systemic mastocytosis (SM)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-06-16",
        "link": "https:\/\/www.prnewswire.com\/news-releases\/fda-approves-blueprint-medicines-ayvakit-avapritinib-for-the-treatment-of-adults-with-advanced-systemic-mastocytosis-301314129.html",
        "note": "FDA approval announced June 16, 2021. ",
        "company_entity_id": 439,
        "company_ticker": "BPMC",
        "company_name": "Blueprint Medicines Corporation",
        "company_price": "89.7000",
        "company_change": 0.23,
        "company_percent_change": 0.26,
        "company_optionable": 1,
        "company_number_of_shares": 61232297,
        "price_change_sparkline": [
            [
                79.53,
                1706677200
            ],
            [
                79.88,
                1706763600
            ],
            [
                79.58,
                1706850000
            ],
            [
                76.66,
                1707109200
            ],
            [
                77.17,
                1707195600
            ],
            [
                74.2,
                1707282000
            ],
            [
                74.16,
                1707368400
            ],
            [
                76.54,
                1707454800
            ],
            [
                77.54,
                1707714000
            ],
            [
                73.17,
                1707800400
            ],
            [
                76.8,
                1707886800
            ],
            [
                87.57,
                1707973200
            ],
            [
                90.26,
                1708059600
            ],
            [
                91.25,
                1708405200
            ],
            [
                87.26,
                1708491600
            ],
            [
                86,
                1708578000
            ],
            [
                89.49,
                1708664400
            ],
            [
                95.05,
                1708923600
            ],
            [
                99.79,
                1709010000
            ],
            [
                95.45,
                1709096400
            ],
            [
                93.52,
                1709182800
            ],
            [
                95.12,
                1709269200
            ],
            [
                90.8,
                1709528400
            ],
            [
                89.67,
                1709614800
            ],
            [
                90.38,
                1709701200
            ],
            [
                92.04,
                1709787600
            ],
            [
                92.3,
                1709874000
            ],
            [
                89.47,
                1710129600
            ],
            [
                89.7,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5995,
        "drug_name": "RYLAZE (JZP458)",
        "clinical_trial_id": "NCT04145531",
        "has_trial_insight_page": 0,
        "indication": "Acute lymphoblastic leukemia (ALL)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-06-30",
        "link": "https:\/\/www.prnewswire.com\/news-releases\/jazz-pharmaceuticals-announces-us-fda-approval-of-rylaze-asparaginase-erwinia-chrysanthemi-recombinant-rywn-for-the-treatment-of-acute-lymphoblastic-leukemia-or-lymphoblastic-lymphoma-301323782.html",
        "note": "FDA approval announced June 30, 2021.",
        "company_entity_id": 627,
        "company_ticker": "LGND",
        "company_name": "Ligand Pharmaceuticals Incorporated",
        "company_price": "72.3600",
        "company_change": 0.11,
        "company_percent_change": 0.15,
        "company_optionable": 1,
        "company_number_of_shares": 17705287,
        "price_change_sparkline": [
            [
                73.1,
                1706677200
            ],
            [
                74.17,
                1706763600
            ],
            [
                74.54,
                1706850000
            ],
            [
                74.72,
                1707109200
            ],
            [
                75.31,
                1707195600
            ],
            [
                74.51,
                1707282000
            ],
            [
                75.41,
                1707368400
            ],
            [
                75.88,
                1707454800
            ],
            [
                75.64,
                1707714000
            ],
            [
                71,
                1707800400
            ],
            [
                73.62,
                1707886800
            ],
            [
                74.65,
                1707973200
            ],
            [
                73.66,
                1708059600
            ],
            [
                72.37,
                1708405200
            ],
            [
                72.67,
                1708491600
            ],
            [
                73.56,
                1708578000
            ],
            [
                75.87,
                1708664400
            ],
            [
                74.42,
                1708923600
            ],
            [
                89.2,
                1709010000
            ],
            [
                84.35,
                1709096400
            ],
            [
                79.35,
                1709182800
            ],
            [
                78.7,
                1709269200
            ],
            [
                76.28,
                1709528400
            ],
            [
                74,
                1709614800
            ],
            [
                72.71,
                1709701200
            ],
            [
                72.47,
                1709787600
            ],
            [
                73.77,
                1709874000
            ],
            [
                72.25,
                1710129600
            ],
            [
                72.36,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5995,
        "drug_name": "RYLAZE (JZP458)",
        "clinical_trial_id": "NCT04145531",
        "has_trial_insight_page": 0,
        "indication": "Acute lymphoblastic leukemia (ALL)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-06-30",
        "link": "https:\/\/www.prnewswire.com\/news-releases\/jazz-pharmaceuticals-announces-us-fda-approval-of-rylaze-asparaginase-erwinia-chrysanthemi-recombinant-rywn-for-the-treatment-of-acute-lymphoblastic-leukemia-or-lymphoblastic-lymphoma-301323782.html",
        "note": "FDA approval announced June 30, 2021.",
        "company_entity_id": 381,
        "company_ticker": "JAZZ",
        "company_name": "Jazz Pharmaceuticals plc",
        "company_price": "115.7900",
        "company_change": -0.84,
        "company_percent_change": -0.72,
        "company_optionable": 1,
        "company_number_of_shares": 62345283,
        "price_change_sparkline": [
            [
                122.72,
                1706677200
            ],
            [
                123.68,
                1706763600
            ],
            [
                122.9,
                1706850000
            ],
            [
                121.98,
                1707109200
            ],
            [
                124.71,
                1707195600
            ],
            [
                122.94,
                1707282000
            ],
            [
                122.67,
                1707368400
            ],
            [
                123.43,
                1707454800
            ],
            [
                124.24,
                1707714000
            ],
            [
                121.83,
                1707800400
            ],
            [
                122.24,
                1707886800
            ],
            [
                126.82,
                1707973200
            ],
            [
                126.78,
                1708059600
            ],
            [
                126.36,
                1708405200
            ],
            [
                128.42,
                1708491600
            ],
            [
                128.45,
                1708578000
            ],
            [
                132.28,
                1708664400
            ],
            [
                132.77,
                1708923600
            ],
            [
                132.26,
                1709010000
            ],
            [
                129.7,
                1709096400
            ],
            [
                118.9,
                1709182800
            ],
            [
                118.85,
                1709269200
            ],
            [
                117.53,
                1709528400
            ],
            [
                118.42,
                1709614800
            ],
            [
                117.19,
                1709701200
            ],
            [
                116.37,
                1709787600
            ],
            [
                117.53,
                1709874000
            ],
            [
                116.63,
                1710129600
            ],
            [
                115.79,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 7476,
        "drug_name": "KEYTRUDA (pembrolizumab)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Cutaneous squamous cell carcinoma (cSCC)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-07-06",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20210706005062\/en\/",
        "note": "FDA approval announced July 6, 2021.",
        "company_entity_id": 383,
        "company_ticker": "MRK",
        "company_name": "Merck & Company Inc.",
        "company_price": "122.6600",
        "company_change": -0.10999999999999999,
        "company_percent_change": -0.08999999999999997,
        "company_optionable": 1,
        "company_number_of_shares": 2532643872,
        "price_change_sparkline": [
            [
                120.78,
                1706677200
            ],
            [
                126.38,
                1706763600
            ],
            [
                126.41,
                1706850000
            ],
            [
                126.18,
                1707109200
            ],
            [
                126.88,
                1707195600
            ],
            [
                127.47,
                1707282000
            ],
            [
                126.61,
                1707368400
            ],
            [
                125.45,
                1707454800
            ],
            [
                125.34,
                1707714000
            ],
            [
                125.43,
                1707800400
            ],
            [
                125.82,
                1707886800
            ],
            [
                126.54,
                1707973200
            ],
            [
                127.79,
                1708059600
            ],
            [
                127.37,
                1708405200
            ],
            [
                128.12,
                1708491600
            ],
            [
                129.26,
                1708578000
            ],
            [
                129.45,
                1708664400
            ],
            [
                128.84,
                1708923600
            ],
            [
                129.03,
                1709010000
            ],
            [
                128.19,
                1709096400
            ],
            [
                127.15,
                1709182800
            ],
            [
                126.96,
                1709269200
            ],
            [
                124.05,
                1709528400
            ],
            [
                122.83,
                1709614800
            ],
            [
                123.75,
                1709701200
            ],
            [
                123.99,
                1709787600
            ],
            [
                123.5,
                1709874000
            ],
            [
                122.77,
                1710129600
            ],
            [
                122.66,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 4988,
        "drug_name": "PADCEV (enfortumab vedotin) - EV-301",
        "clinical_trial_id": "NCT03474107",
        "has_trial_insight_page": 0,
        "indication": "Urothelial cancer",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-07-09",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20210709005414\/en\/",
        "note": null,
        "company_entity_id": 387,
        "company_ticker": "PFE",
        "company_name": "Pfizer Inc.",
        "company_price": "28.0100",
        "company_change": -0.36,
        "company_percent_change": -1.27,
        "company_optionable": 1,
        "company_number_of_shares": 5646778425,
        "price_change_sparkline": [
            [
                27.08,
                1706677200
            ],
            [
                27.29,
                1706763600
            ],
            [
                26.93,
                1706850000
            ],
            [
                26.57,
                1707109200
            ],
            [
                27.5,
                1707195600
            ],
            [
                27.56,
                1707282000
            ],
            [
                27.57,
                1707368400
            ],
            [
                27.56,
                1707454800
            ],
            [
                27.66,
                1707714000
            ],
            [
                26.97,
                1707800400
            ],
            [
                27.11,
                1707886800
            ],
            [
                27.51,
                1707973200
            ],
            [
                27.62,
                1708059600
            ],
            [
                27.59,
                1708405200
            ],
            [
                27.67,
                1708491600
            ],
            [
                27.55,
                1708578000
            ],
            [
                27.76,
                1708664400
            ],
            [
                27.18,
                1708923600
            ],
            [
                26.89,
                1709010000
            ],
            [
                27.04,
                1709096400
            ],
            [
                26.56,
                1709182800
            ],
            [
                26.59,
                1709269200
            ],
            [
                25.89,
                1709528400
            ],
            [
                26.08,
                1709614800
            ],
            [
                27.19,
                1709701200
            ],
            [
                26.79,
                1709787600
            ],
            [
                27.22,
                1709874000
            ],
            [
                28.37,
                1710129600
            ],
            [
                28.01,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 7147,
        "drug_name": "DARZALEX (Daratumumab) in combination with Pomalyst (pomalidomide) and dexamethasone",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Multiple myeloma",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-07-12",
        "link": "https:\/\/www.prnewswire.com\/news-releases\/halozyme-announces-janssen-receives-us-fda-approval-of-darzalex-faspro-daratumumab-and-hyaluronidase-fihj-in-combination-with-pomalidomide-and-dexamethasone-for-patients-with-multiple-myeloma-after-first-or-subsequent-relapse-301331450.html",
        "note": "FDA approval announced July 12, 2021.",
        "company_entity_id": 380,
        "company_ticker": "JNJ",
        "company_name": "Johnson & Johnson",
        "company_price": "162.7400",
        "company_change": 1.51,
        "company_percent_change": 0.94,
        "company_optionable": 1,
        "company_number_of_shares": 2408767228,
        "price_change_sparkline": [
            [
                157.701248890579,
                1706677200
            ],
            [
                157.165322682896,
                1706763600
            ],
            [
                155.428524787625,
                1706850000
            ],
            [
                154.6246354761,
                1707109200
            ],
            [
                156.867585900849,
                1707195600
            ],
            [
                156.788189425637,
                1707282000
            ],
            [
                155.220109040193,
                1707368400
            ],
            [
                155.577393178648,
                1707454800
            ],
            [
                156.659170153417,
                1707714000
            ],
            [
                155.289580956004,
                1707800400
            ],
            [
                154.565088119691,
                1707886800
            ],
            [
                156.728642069228,
                1707973200
            ],
            [
                156.55,
                1708059600
            ],
            [
                157.86,
                1708405200
            ],
            [
                158.68,
                1708491600
            ],
            [
                160.45,
                1708578000
            ],
            [
                161.84,
                1708664400
            ],
            [
                160.79,
                1708923600
            ],
            [
                160.98,
                1709010000
            ],
            [
                161.55,
                1709096400
            ],
            [
                161.38,
                1709182800
            ],
            [
                162.12,
                1709269200
            ],
            [
                159.84,
                1709528400
            ],
            [
                159.97,
                1709614800
            ],
            [
                159.34,
                1709701200
            ],
            [
                158.87,
                1709787600
            ],
            [
                159.52,
                1709874000
            ],
            [
                161.23,
                1710129600
            ],
            [
                162.74,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 7147,
        "drug_name": "DARZALEX (Daratumumab) in combination with Pomalyst (pomalidomide) and dexamethasone",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Multiple myeloma",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-07-12",
        "link": "https:\/\/www.prnewswire.com\/news-releases\/halozyme-announces-janssen-receives-us-fda-approval-of-darzalex-faspro-daratumumab-and-hyaluronidase-fihj-in-combination-with-pomalidomide-and-dexamethasone-for-patients-with-multiple-myeloma-after-first-or-subsequent-relapse-301331450.html",
        "note": "FDA approval announced July 12, 2021.",
        "company_entity_id": 156,
        "company_ticker": "HALO",
        "company_name": "Halozyme Therapeutics Inc.",
        "company_price": "41.9500",
        "company_change": 0.75,
        "company_percent_change": 1.8199999999999998,
        "company_optionable": 1,
        "company_number_of_shares": 126824800,
        "price_change_sparkline": [
            [
                33.85,
                1706677200
            ],
            [
                34.26,
                1706763600
            ],
            [
                33.68,
                1706850000
            ],
            [
                33.68,
                1707109200
            ],
            [
                35.02,
                1707195600
            ],
            [
                35.31,
                1707282000
            ],
            [
                35.24,
                1707368400
            ],
            [
                35.49,
                1707454800
            ],
            [
                35.69,
                1707714000
            ],
            [
                34.64,
                1707800400
            ],
            [
                35.06,
                1707886800
            ],
            [
                35.91,
                1707973200
            ],
            [
                36.1,
                1708059600
            ],
            [
                36,
                1708405200
            ],
            [
                38.36,
                1708491600
            ],
            [
                39.72,
                1708578000
            ],
            [
                40.56,
                1708664400
            ],
            [
                39.67,
                1708923600
            ],
            [
                39.84,
                1709010000
            ],
            [
                39.69,
                1709096400
            ],
            [
                39.81,
                1709182800
            ],
            [
                41.11,
                1709269200
            ],
            [
                40.93,
                1709528400
            ],
            [
                41.41,
                1709614800
            ],
            [
                41.69,
                1709701200
            ],
            [
                41.71,
                1709787600
            ],
            [
                41.73,
                1709874000
            ],
            [
                41.2,
                1710129600
            ],
            [
                41.95,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 6195,
        "drug_name": "VAXNEUVANCE",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Pneumococcal disease",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-07-16",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20210716005480\/en\/",
        "note": "FDA approval announced July 16, 2021.",
        "company_entity_id": 627,
        "company_ticker": "LGND",
        "company_name": "Ligand Pharmaceuticals Incorporated",
        "company_price": "72.3600",
        "company_change": 0.11,
        "company_percent_change": 0.15,
        "company_optionable": 1,
        "company_number_of_shares": 17705287,
        "price_change_sparkline": [
            [
                73.1,
                1706677200
            ],
            [
                74.17,
                1706763600
            ],
            [
                74.54,
                1706850000
            ],
            [
                74.72,
                1707109200
            ],
            [
                75.31,
                1707195600
            ],
            [
                74.51,
                1707282000
            ],
            [
                75.41,
                1707368400
            ],
            [
                75.88,
                1707454800
            ],
            [
                75.64,
                1707714000
            ],
            [
                71,
                1707800400
            ],
            [
                73.62,
                1707886800
            ],
            [
                74.65,
                1707973200
            ],
            [
                73.66,
                1708059600
            ],
            [
                72.37,
                1708405200
            ],
            [
                72.67,
                1708491600
            ],
            [
                73.56,
                1708578000
            ],
            [
                75.87,
                1708664400
            ],
            [
                74.42,
                1708923600
            ],
            [
                89.2,
                1709010000
            ],
            [
                84.35,
                1709096400
            ],
            [
                79.35,
                1709182800
            ],
            [
                78.7,
                1709269200
            ],
            [
                76.28,
                1709528400
            ],
            [
                74,
                1709614800
            ],
            [
                72.71,
                1709701200
            ],
            [
                72.47,
                1709787600
            ],
            [
                73.77,
                1709874000
            ],
            [
                72.25,
                1710129600
            ],
            [
                72.36,
                1710216000
            ]
        ],
        "statuses": []
    }
]